Our novel findings with KYNA or SZR-72 administration in experimental AP are the following: They (1) dose-dependently reduced the severity of the disease; (2) reduced the proinflammatory cytokine IL-1β expression in vivo; (3) increased the synthesis of HSP72; (4) reduced the extent of metabolic acidosis; (5) restored pancreatic microcirculation; (6) suppressed the function of neutrophil granulocytes. The gene discussed is IL1B; the disease is alkaline phosphatase measurement.